期刊文献+

中西医结合治疗糖尿病肾病的临床研究 被引量:4

Clinical Study on the Treatment of Diabetic Nephropathy With Combination of Traditional Chinese And Western Medicine
下载PDF
导出
摘要 目的:观察非洛地平片联合五苓散加减治疗糖尿病肾病的临床疗效,探讨中西医结合治疗糖尿病肾病的优势。材料与方法:纳入l20例糖尿病肾病患者,随机分为对照组和治疗组,在运用基础降糖治疗基础上,两组均使用非洛地平片降压,治疗组加用五苓散加减,疗程为2个月。重点观察患者尿微量白蛋白排泄率(UAER)的变化,并观察患者血肌酐(Scr)、尿素氮(BUN)、尿酸(UA)、平均动脉压均(MAP)及糖化血红蛋白的变化。结果:治疗组总有效率为96.7%,明显优于对照组(P<0.01);治疗2月后尿微量白蛋白排泄率(UAER)及血肌酐(Scr)均有所改善,治疗组优于对照组(P<0.01);而在糖化血红蛋白、尿素氮(BUN)、尿酸(u A)及平均动脉压均(MAP)方面具有不同程度的改善,但组间对比(P>0.05)差异不大,结论:两组均有改善糖尿病肾病患者的微量白蛋白尿排泄率。而中西医结合(非洛地平联合五苓散加减)的治疗方法效果更明显: Purpose: To observe the clinical efficacy of felodipine tablets combined with Wuling powder Decoction in the treatment of diabetic nephropathy( DN) and investigate the advantage of combination of traditional Chinese and Western Medicine. Materials and Methods: 120 patients with DN were randomly divided into control group and treatment group. On the basis of the use of basic hypoglycemic therapy,patients in both group took Felodipine Tablets to control blood pressure while patients in the treatment group were additionally treated with Wuling powder Decoction for 2 months. The changes of urinary albumin excretion rate( UAER),serum creatinine( Scr),blood urea nitrogen( BUN),uric acid( UA),mean arterial pressure( MAP) and glycosylated hemoglobin were observed. Results: The total effective rate of the treatment group was96. 7%,which was significantly better than that of the control group( P 0. 01). The UAER and Scr were improved after treatment for 2 months,and the treatment group was better than the control group( P 0. 01). While glycosylated hemoglobin,BUN,UA and MAP were improved in different degrees,no significant difference was found between the two groups( P 0. 05). Conclusion: The UAER was improved in both groups,but the curative effect of combination of traditional Chinese and Western Medicine( felodipine tablets combined with Wuling powder Decoction) is more remarkable.
作者 卓少平
出处 《现代医用影像学》 2016年第4期795-797,共3页 Modern Medical Imageology
关键词 糖尿病肾病 非洛地平 五苓散加减 尿微量白蛋白排泄率 diabetic nephropathy felodipine Wuling powder Decoction urinary albumin excretion rate
  • 相关文献

参考文献7

  • 1Yang WY, Lu JM, Weng J P, et al. Prevalence of Diabetes among Men and Women in China [ J 1- NEnglJMed, 2010, 25, 362(12): 1090 -1101.
  • 2陈莉明.从中国糖尿病防治指南看糖尿病肾病的诊断和治疗[J].中国实用内科杂志,2009,29(6):513-516. 被引量:74
  • 3De Ferrarl G. Guidelines for diagnosis and therapy of diabet;~c nephropathy [ J ]. J Ital Nephrol, 2008, 20 (Supp]24) : $ 96 - S108.
  • 4杨丽,梅长林.解读美国糖尿病及慢性肾脏病临床实践指南[J].中华肾脏病杂志,2007,23(10):681-684. 被引量:49
  • 5中国糖尿病防治指南编写组.中国糖尿病防治指南[M].北京:北京大学医学出版社,2009:132-137.
  • 6Mogensen CE. Early domemlar hyperfihration jn insulinde- pendent diabetics and late nephropathy[ J]. Scand J Clin Lab Invest, 2008, 46:201 -206.
  • 7郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2011:388.

二级参考文献11

  • 1KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
  • 2Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
  • 3Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
  • 4Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
  • 5Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
  • 6Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
  • 7Rossing K,Christensen PK,Andersen S,et al.Comparative effects of lrbosartan on ambulatory and office blood pressure:a substudy of ambulatory blood pressure from the lrbesartan in Patients with Type 2 Diabetes and Micreslbuminuria study[J].Diabetes Care,2003,26:569-574.
  • 8Diercks GF,Janssen WM,van Boven AJ,et al.Rationale,design,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive,nonhypercholesterolemic subjects with microalbuminuria(the Prevention of REnal and Vascular ENdstage Disease Intervention Trial[PREVEND IT])[J].Am J Cardiol,2000,86:635-638.
  • 9Ansquer JC,Fouchor C,Rattier S,et al.Fenofibrate reduces progresaion to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS).[J] Am J Kidney Dis,2005,45:485-493.
  • 10American Diabetes Association.Standards of Medical Care in Diabetes-2009[J].Diabetes Care,2009,32 (Suppl 1):S13 -61.

共引文献121

同被引文献21

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部